How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Magnetic Levitation Left Ventricular Assist Device (LVAD) Market
- By Product Type: Intracorporeal LVAD, Extracorporeal LVAD, Paracorporeal LVAD
- By Flow Type: Continuous Flow LVAD, Pulsatile Flow LVAD
- By Indication: Bridge to Transplant (BTT), Destination Therapy (DT), Bridge to Recovery (BTR), Bridge to Candidacy (BTC)
- By End User: Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers
- By Technology: Magnetic Levitation Bearing Systems, Hydrodynamic Bearing Systems, Mechanical Bearing Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Intracorporeal LVAD leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.170 →
- 12 Company Profiles 11 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Magnetic Levitation Left Ventricular Assist Device (LVAD) Market report
A complete, evidence-based study - 12 chapters and 114 sections covering market size, segmentation across 5 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Product Type 3
Flow Type 2
Indication 4
End User 3
Technology 3
Companies profiled
Abbott Laboratories
Medtronic plc
Berlin Heart GmbH
CARMAT
SynCardia Systems
LLC
Abiomed Inc.
Jarvik Heart Inc.
Thoratec Corporation (acquired by Abbott)
HeartWare International
Inc. (acquired by Medtronic)
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Berlin Heart GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →CARMAT
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →SynCardia Systems
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Abiomed Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Jarvik Heart Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Thoratec Corporation (acquired by Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →HeartWare International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Inc. (acquired by Medtronic)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,830M by 2033 · 3.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Intracorporeal LVAD60.7
- Extracorporeal LVAD17.2
- Paracorporeal LVAD22.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$457.9M → $590.2M · 3.2%
Europe$319.1M → $454.7M · 4.5%
Asia Pacific$291.4M → $402.9M · 4.1%
Latin America$180.4M → $224.9M · 2.8%
Middle East and Africa$138.8M → $170.6M · 2.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.472026
3.482027
3.492028
3.522029
3.532030
3.542031
3.542032
3.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories14.3
- Medtronic plc17.3
- Berlin Heart GmbH9.6
- CARMAT7.7
- SynCardia Systems8.9
- LLC14.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type21.4%
Flow Type24.7%
Indication14.7%
End User18.0%
Technology21.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe24.7
- Asia Pacific21.9
- Latin America12.2
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 88 | 80 | 88 | 96 | 95 | 87 | 89 |
| Medtronic plc | 84 | 72 | 84 | 75 | 81 | 85 | 80 |
| Berlin Heart GmbH | 86 | 85 | 77 | 64 | 81 | 64 | 76 |
| CARMAT | 70 | 79 | 72 | 60 | 78 | 78 | 73 |
| SynCardia Systems | 52 | 67 | 58 | 62 | 75 | 53 | 61 |
| LLC | 62 | 55 | 71 | 46 | 66 | 58 | 60 |
| Abiomed Inc. | 42 | 59 | 56 | 47 | 58 | 46 | 51 |
| Jarvik Heart Inc. | 44 | 47 | 39 | 53 | 56 | 55 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Medtronic plc
- Berlin Heart GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Medtronic plc | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Berlin Heart GmbH | ✓ | ◐ | ◐ | − | ✓ | ◐ |
| CARMAT | ✓ | ◐ | − | ◐ | ◐ | ◐ |
| SynCardia Systems | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| LLC | ◐ | − | ✓ | − | − | − |
| Abiomed Inc. | − | ◐ | ◐ | − | − | − |
| Jarvik Heart Inc. | ◐ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories89
2Medtronic plc80
3Berlin Heart GmbH76
4CARMAT73
5SynCardia Systems61
6LLC60
7Abiomed Inc.51
8Jarvik Heart Inc.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesMedtronic plc
Challenger2
Strong scale, closing on the leaders.
Berlin Heart GmbHCARMAT
Contender2
Focused players with pockets of strength.
SynCardia SystemsLLC
Niche2
Specialists in a single segment or region.
Abiomed Inc.Jarvik Heart Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Magnetic Levitation Left Ventricular Assist Device (LVAD) Market — a $296M beachhead inside a $4.81B market.
Beachhead (SOM)$296Mobtainable near-term
Serviceable (SAM)$1.93Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Intracorporeal LVAD
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Extracorporeal LVAD
Strong fit — clear ROI and a fast path to value.
End user64 fit
Paracorporeal LVAD
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Flow Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel27%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Magnetic Levitation Left Ventricular Assist Device (LVAD) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified23%
Evaluation13%
Closed-won7%
$13.1KCAC
$62KLTV
4.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Magnetic Levitation Left Ventricular Assist Device (LVAD) Market is a high-growth opportunity — $10.0B by 2033, compounding at 10.3%.
TAM · 2025$4.59Btoday
TAM · 2033$10.0Bforecast
CAGR10.3%2027–2033
Cumulative$63.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.0BTotal addressable market
SAM$3.62BServiceable available market
SOM$773MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.0BLarge & growingTAM by 2033 at 10.3% CAGR
$3.62BServiceable nowreachable with today’s model
$773MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.82BBear6.7% CAGR
$10.0BBase10.3% CAGR
$12.8BBull13.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Flow Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Magnetic Levitation Left Ventricular Assist Device (LVAD) Market — a $1.10B market by 2033. Plan: grow share from 11.0% to 17.4%.
Market size · 2033$1.10Btotal addressable
Market CAGR4.7%2027–2033
Target share17.4%from 11.0% today
Revenue ambition$191Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.0% | 17.4% | On track |
| Revenue | $110M | $191M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.5% | 38.5% | On track |
| Customer retention | 85.4% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Flow Type capability
A defensible second engine — invest in Flow Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Flow Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in Flow Type
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Magnetic Levitation Left Ventricular Assist Device (LVAD) Market conversation — a $1.93B market you can size, segment and defend in minutes.
Market size · 2033$1.93Btotal opportunity
Growth6.5%CAGR to 2033
Addressable buyers1,671+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
Abbott LaboratoriesMedtronic plcBerlin Heart GmbHCARMATSynCardia SystemsLLCAbiomed Inc.Jarvik Heart Inc.+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Magnetic Levitation Left Ventricular Assist Device (LVAD) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Magnetic Levitation Left Ventricular Assist Device (LVAD) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Magnetic Levitation Extracorporeal Life-support (ECLS) System Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportMagnetic Levitation Bearingless Extracorporeal Life-support (ECLS) Blood Pump Market
Market size, share, segmentation and regional forecast.
$476M market · 2025 base year
View reportMagnetic Levitation Bearingless Blood Pump Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportMagnetic Levitation Artificial Heart Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportMagnetic Laboratory Shaker Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportMagnetic Induction Electrotherapy Machine Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMagnetic Induction Electrotherapy Equipment Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportMagnetic Hyperthermia and Radiation Therapy Devices Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportMagnetic Denture Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportMagnetic Coupled Mixer for Pharmaceuticals & Biotech Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMagnetic Coupled Mixer for Pharmaceutical Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportMagnetic Compensation Analytical Balance Market
Market size, share, segmentation and regional forecast.
$461M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.